Is there an ideal animal model for SARS?

Trends in Microbiology

Volumn 14, Issue 7, 2006, Pages 299-303

  Subbarao, Kanta ^a   Roberts, Anjeanette ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; INACTIVATED VACCINE; MONOCLONAL ANTIBODY; POLYCLONAL ANTISERUM;

ARTICLE; DISEASE SEVERITY; FERRET; HAMSTER; IMMUNOTHERAPY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS IDENTIFICATION;

ANIMALS; CERCOPITHECIDAE; CRICETINAE; DISEASE MODELS, ANIMAL; FERRETS; HUMANS; MICE; PLATYRRHINI; REPRODUCIBILITY OF RESULTS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

ANIMALIA;

EID: 33745514661     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2006.05.007     Document Type: Article

References (39)

1. Drosten C., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1967-1976
2. Ksiazek T.G., et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1953-1966
3. Peiris J.S., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 (2003) 1319-1325
4. Poutanen S.M., et al. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 348 (2003) 1995-2005
5. Guan Y., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China. Science 302 (2003) 276-278
6. Li W., et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310 (2005) 676-679
7. Lau S.K., et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 14040-14045
8. Subbarao K., et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J. Virol. 78 (2004) 3572-3577
9. Wentworth D.E., et al. Mice susceptible to SARS coronavirus. Emerg. Infect. Dis. 10 (2004) 1293-1296
10. Glass W.G., et al. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J. Immunol. 173 (2004) 4030-4039
11. Hogan R.J., et al. Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J. Virol. 78 (2004) 11416-11421
12. Roberts A., et al. Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J. Virol. 79 (2005) 5833-5838
13. Bisht H., et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 6641-6646
14. Bisht H., et al. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology 334 (2005) 160-165
15. Greenough T.C., et al. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J. Infect. Dis. 191 (2005) 507-514
16. Kapadia S.U., et al. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340 (2005) 174-182
17. Stadler K., et al. SARS vaccine protective in mice. Emerg. Infect. Dis. 11 (2005) 1312-1314
18. See R.H., et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J. Gen. Virol. 87 (2006) 641-650
19. Shi S.Q., et al. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. Mol. Immunol. 43 (2006) 1791-1798
20. Spruth M., et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 24 (2006) 652-661
21. Sui J., et al. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J. Virol. 79 (2005) 5900-5906
22. Traggiai E., et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10 (2004) 871-875
23. Yang Z.Y., et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428 (2004) 561-564
24. Roberts A., et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J. Virol. 79 (2005) 503-511
25. Roberts A., et al. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J. Infect. Dis. 193 (2006) 685-692
26. Martina B.E., et al. Virology: SARS virus infection of cats and ferrets. Nature 425 (2003) 915
27. ter Meulen J., et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363 (2004) 2139-2141
28. Weingartl H., et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78 (2004) 12672-12676
29. Fouchier R.A., et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423 (2003) 240
30. Kuiken T., et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362 (2003) 263-270
31. McAuliffe J., et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology 330 (2004) 8-15
32. Qin C., et al. An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J. Pathol. 206 (2005) 251-259
33. Rowe T., et al. Macaque model for severe acute respiratory syndrome. J. Virol. 78 (2004) 11401-11404
34. Greenough T.C., et al. Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus. Am. J. Pathol. 167 (2005) 455-463
35. Buchholz U.J., et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9804-9809
36. Bukreyev A., et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363 (2004) 2122-2127
37. Peiris J.S., et al. Severe acute respiratory syndrome. Nat. Med. 10 (2004) S88-S97
38. Zhou J., et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine 23 (2005) 3202-3209
39. Chen Z., et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. 79 (2005) 2678-2688